Anika Therapeutics Reports 1Q19 Orthobiologic Revenue of $21.7MM, +11.6% vs. 1Q18

Anika Therapeutics reported 1Q19 orthobiologic revenue of USD $21.7MM, +11.6% vs. 1Q18.

Growth driven by higher global revenue of viscosupplements and HYAFF-based products
Ex-U.S. sales of single injection treatments up 18%
Remain on track for 2H19 launch of bone repair therapy product with expected U.S. market opportunity of $250...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0